Free Trial

Medpace Q2 2023 Earnings Report

Medpace logo
$324.51 -6.08 (-1.84%)
As of 04:00 PM Eastern

Medpace EPS Results

Actual EPS
$1.93
Consensus EPS
$1.90
Beat/Miss
Beat by +$0.03
One Year Ago EPS
$1.46

Medpace Revenue Results

Actual Revenue
$460.90 million
Expected Revenue
$433.75 million
Beat/Miss
Beat by +$27.15 million
YoY Revenue Growth
+31.20%

Medpace Announcement Details

Quarter
Q2 2023
Time
After Market Closes

MEDP Upcoming Earnings

Medpace will be holding an earnings conference call on Tuesday, April 22 at 9:00 AM Eastern. Interested parties can register for or listen to the call.

Conference Call Resources

Remove Ads

Medpace Earnings Headlines

Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
Medpace initiated with a Market Perform at Leerink
See More Medpace Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medpace? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medpace and other key companies, straight to your email.

About Medpace

Medpace (NASDAQ:MEDP) engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

View Medpace Profile

More Earnings Resources from MarketBeat